Advanced search
Publication Cover
Current Medical Research and Opinion Volume 25, 2009 - Issue 9
Submit an article Journal homepage
306
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

Enrique Hernandez Temple University Hospital, Philadelphia, PA, USA
,
Peter Ganly Canterbury Health Laboratories, Christchurch, New Zealand
,
Veena Charu Pacific Cancer Medical Center, Anaheim, CA, USA
,
Joseph DiBenedetto Oncology Hematology Associates, Providence, RI, USA
,
Dianne Tomita Amgen Inc., Thousand Oaks, CA, USA
,
Tom Lillie Amgen Inc., Thousand Oaks, CA, USA
,
Kerry Taylor Mater Medical Centre Level 5, South Brisbane, Queensland, AustraliaCorrespondence[email protected]
& for the ARANESP 20030232 Study Group show all
Pages 2109-2120 | Accepted 02 Jun 2009, Published online: 14 Jul 2009

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Jean-Loup Mouysset, Beata Freier, Joan van den Bosch, Charles Briac Levaché, Alain Bols, Hans Werner Tessen, Laura Belton, G Chet Bohac, Jan-Henrik Terwey & Giuseppe Tonini. (2016) Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study. Cancer Management and Research 8, pages 1-10.
Read now
Isabelle Wauters & Johan Vansteenkiste. (2012) Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Expert Review of Anticancer Therapy 12:11, pages 1383-1390.
Read now
S. Van Belle, A. Swieboda-Sadlej, C. Karanikiotis, J.-L. Labourey, A. Galid, T. Wheeler, B. Pujol & J.G. Aerts. (2012) A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice. Current Medical Research and Opinion 28:7, pages 1079-1087.
Read now
S. Van Belle, C. Karanikiotis, J.-L. Labourey, A. Galid, T. Wheeler & B. Pujol. (2011) Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy – data from the CHOICE study. Current Medical Research and Opinion 27:5, pages 987-994.
Read now

Articles from other publishers (17)

Anne Adams, Benjamin Scheckel, Anissa Habsaoui, Madhuri Haque, Kathrin Kuhr, Ina Monsef, Julia Bohlius & Nicole Skoetz. (2022) Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2022:6.
Crossref
Sanjay Rao Gergal Gopalkrishna Rao, Seif Bugazia, Tamil Poonkuil Mozhi Dhandapani, Anjli Tara, Ishan Garg, Jaimin N Patel, Jimin Yeon, Marrium S Memon, Abilash Muralidharan & Safeera Khan. (2021) Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. Cureus.
Crossref
Paul Cornes & Matti Aapro. (2018) The Impact of Biosimilars in Supportive Care in Cancer. European Oncology & Haematology 14:1, pages 20.
Crossref
Ralph V. Boccia, David H. Henry, Laura Belton, Chet Bohac & Hassan H. Ghazal. (2016) Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia. Cancer Medicine 5:12, pages 3445-3453.
Crossref
Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier & Chris Hyde. (2016) The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technology Assessment 20:13, pages 1-588.
Crossref
Robert Pirker, Michael Hedenus, Johan Vansteenkiste, Enrique Hernandez, Laura Belton & Jan-Henrik Terwey. (2016) Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL. Clinical Therapeutics 38:1, pages 122-135.e6.
Crossref
César A. Rodríguez Sánchez, Adrián Alegre, Javier Cassinello, Laura Gutiérrez, Carlos Crespo, Alba Villacampa & Evelyn Walter. (2013) Coste-efectividad del tratamiento de la anemia inducida por quimioterapia con agentes estimuladores de la eritropoyesis. PharmacoEconomics Spanish Research Articles 11:4, pages 109-121.
Crossref
Nataša Debeljak, Peter Solár & Arthur J. Sytkowski. (2014) Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction. Frontiers in Immunology 5.
Crossref
J Bohlius, T Tonia, E Nüesch, P Jüni, M F Fey, M Egger & J Bernhard. (2014) Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. British Journal of Cancer 111:1, pages 33-45.
Crossref
Thomas Thomaidis, Arndt Weinmann, Martin Sprinzl, Stephan Kanzler, Jochen Raedle, Matthias Ebert, Carl Cristoph Schimanski, Peter Robert Galle, Thomas Hoehler & Markus Moehler. (2013) Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. International Journal of Clinical Oncology 19:2, pages 288-296.
Crossref
Sheng Gao, Jing-Jing Ma & Cheng Lu. (2013) Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumor Biology 35:1, pages 603-613.
Crossref
Jerrold W. Hill, Sanatan Shreay, November McGarvey, Ajita P. De, Gregory P. Hess & Patricia K. Corey-Lisle. (2013) Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits. Supportive Care in Cancer 21:11, pages 2957-2965.
Crossref
Robert Pirker, Melissa Pirolli, Jane Quigley, Scott Hulnick, Jason Legg, Helen Collins & Johan Vansteenkiste. (2012) Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent. Supportive Care in Cancer 21:4, pages 987-992.
Crossref
Thomy Tonia, Annette Mettler, Nadège Robert, Guido Schwarzer, Jerome Seidenfeld, Olaf Weingart, Chris Hyde, Andreas Engert & Julia Bohlius. (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews.
Crossref
Johan Vansteenkiste, John Glaspy, David Henry, Heinz Ludwig, Robert Pirker, Dianne Tomita, Helen Collins & Jeffrey Crawford. (2012) Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. Lung Cancer 76:3, pages 478-485.
Crossref
J. Douglas RizzoMelissa BrouwersPatricia HurleyJerome SeidenfeldMurat O. ArcasoyJerry L. SpivakCharles L. BennettJulia BohliusDarren EvanchukMatthew J. GoodeAnn A. JakubowskiDavid H. ReganMark R. Somerfield. (2010) American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. Journal of Clinical Oncology 28:33, pages 4996-5010.
Crossref
J. Douglas RizzoMelissa BrouwersPatricia HurleyJerome SeidenfeldMurat O. ArcasoyJerry L. SpivakCharles L. BennettJulia BohliusDarren EvanchukMatthew J. GoodeAnn A. Jakubowski, David H. Regan & Mark R. Somerfield. (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116:20, pages 4045-4059.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.